Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

• Hoofdauteurs: Rasoul Akbari (Auteur), Tahereh Behdarvand (Auteur), Reza Afarin (Auteur), Hamid Yaghooti (Auteur), Mohammad Taha Jalali (Auteur), Narges Mohammadtaghvaei (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2021-10-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate, a PPAR-α agonist, and pioglitazone, a...